Globus gains FDA OK for spinal disc

Globus Medical got FDA approval for its Secure-C spinal implant--courtesy of Globus Medical

Globus Medical ($GMED) got FDA approval for Secure-C, the company's spinal disc replacement device, saying the tech is demonstrably more successful than current surgeries for disc abnormalities.

The device is an articulating intervertebral disc replacement, and a 380-patient study showed that Secure-C is safer and more effective than the standard-of-care anterior cervical discectomy and fusion surgery, Globus says. Secure-C is implanted to replace diseased or bulging discs, and the device can stabilize the spine while still allowing motion at the operated disc, unlike any other product on the market.

"Secure-C's selectively constrained design allows a natural range of motion, including translation, while preventing dissociation," Globus Vice President Michael Boyer said in a statement.

The approval and launch of Secure-C is Globus' first big step as a publicly traded company. The Audubon, PA, devicemaker pulled in $100 million in its IPO in August, after scaling back expectations from a planned $200 million offering earlier this year.

Founded in 2003, Globus markets more than 100 products to treat spinal disorders, and, the company brought in $331.5 million in sales last year. Globus estimates the world spine market at about $10 billion and says an aging population and growing number of spinal procedures will only push that number northward.

- read Globus' release

Suggested Articles

The agency also gave the company’s diagnostic, run on the high-throughput Panther Fusion laboratory platform, a green light for pooled testing.

Smith & Nephew has signed up to acquire Integra LifeSciences’ orthopedics business focused on the growing upper and lower extremity markets.

The company describes the continuous glucose monitor as the world’s smallest and thinnest diabetes sensor, with a disc about the size of two pennies.